Retension Pharmaceuticals Announces Formation of Scientific Advisory BoardRetension Pharmaceuticals, Inc. (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, today announced the formation of its Scientific Advisory Board (SAB). The SAB is expected to provide strategic guidance as well as scientific, clinical trial, and therapeutic area expertise as Retension advances RTN-001 in clinical development in the ongoing Phase 2b clinical trial in patients with hypertension.
Retension Pharmaceuticals Appoints LeAnne Bloedon, M.S., RD, as EVP of Clinical Development and Operations, and Kevin Schutz, PharmD, as VP Regulatory Affairs
Retension Pharmaceuticals, Inc. (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, today announced that LeAnne Bloedon, M.S., RD, and Kevin Schutz, PharmD, have joined the Company as Executive Vice President, Clinical Development and Operations, and as Vice President, Regulatory Affairs, respectively.
Retension Pharmaceuticals Closes $10.4 Million Oversubscribed Series A to Fund Clinical Trials for Patients Suffering from Resistant and Uncontrolled Hypertension
Retension Pharmaceuticals, Inc. is pleased to announce the successful closing of its Series A $10.4 million financing round to initiate a well-powered and controlled Phase 2 clinical study in patients with hypertension uncontrolled on two or more antihypertensives.
